Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10306884" target="_blank" >RIV/00216208:11110/15:10306884 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/15:10306884
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1501481" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1501481</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1501481" target="_blank" >10.1056/NEJMoa1501481</a>
Alternative languages
Result language
angličtina
Original language name
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Original language description
BACKGROUND: Daclizumab high-yield process (HYP) is a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling. Abnormalities in interleukin-2 signaling have been implicated in the pathogenesis of multiple sclerosis and other autoimmune disorders. METHODS: We conducted a randomized, double-blind, active-controlled, phase 3 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare daclizumab HYP, administered subcutaneously at a dose of 150 mg every 4 weeks, with interferon beta-1a, administered intramuscularly at a dose of 30 mu g once weekly, for up to 144 weeks. The primary end point was the annualized relapse rate. CONCLUSIONS: Among patients with relapsing-remitting multiple sclerosis, daclizumab HYP showed efficacy superior to that of interferon beta-1a with regard to the annualized relapse rate and lesions, as assessed by means of MRI, but was not associated with a significantly
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
373
Issue of the periodical within the volume
15
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
1418-1428
UT code for WoS article
000362372800008
EID of the result in the Scopus database
2-s2.0-84943562782